Rabeprazole: a pharmacologic and clinical review for acid-related disorders

Bibliography

• Kromer W, Kruger U, Huber R, et al. Differences in pH-dependent activation rates of substituted benzimidazole and biolgical in vitro correlates. Pharmacology 1998;56:57-70
   PubMed Web of Science ®Google Scholar
• Besancon M, Simon A, Sachs G, et al. Sites of reaction of the gastric H,K-TEPase with extracytoplasmic thiol reagents. J Biol Chem 1997;272:22438-46
   PubMed Web of Science ®Google Scholar
• Miner P Jr, Katz P, Chen Y, et al. Gastric-acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole. A five-way crossover study. Am J Gastroenterol 2003;98:2616-20
   PubMed Web of Science ®Google Scholar
• Burget DW, Chiverton SG, Hunt RH. Is there an optimal degree of acid suppression for healing duodenal ulcers? A model of the relationship between ulcer healing and acid suppression. Gastroenterology 1990;99:345-51
   PubMed Web of Science ®Google Scholar
• Bell NJ, Burget D, Howden CW, et al. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion 1992;51(Suppl 1):59-67
   PubMed Web of Science ®Google Scholar
• Williams MP, Sercombe J, Hamilton MI, et al. A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastrtic acidity and plasma gastrin concentration in young healthy male subjects. Aliment Pharmacol Ther 1998;12:1079-89
   PubMed Web of Science ®Google Scholar
• Pantoflicka D, Dorta G, Ravic M, et al. Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors. Aliment Pharmacol Ther 2003;17:1507-14
   PubMed Web of Science ®Google Scholar
• Swan SK, Hoyumpa AM, Merritt GJ. Review article: the pharmacokinetics of rabeprazole in health and disease. Aliment Pharmacol Ther 1999;13(Suppl 3):11-17
   PubMed Web of Science ®Google Scholar
• Fuhr U, Jetter A. Rabeprazole; pharmacokinetics and pharmacokinetic drug interactions. Pharmazie 2002;57:595-601
   PubMed Web of Science ®Google Scholar
• Thjodleifsson B. Review of rabeprazole in the treatment of gastro-oesosophageal reflux disease. Expert Opin Pharmacother 2004;5:137-49
   PubMed Web of Science ®Google Scholar
• Adachi K, Katsube T, Kawamura A, et al. CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole. Aliment Pharmacol Ther 2000;14:1259-66
   PubMed Web of Science ®Google Scholar
• Furuta T, Shirai N, Sugimoto M, et al. Influence of CYP2C19 pharmacogenetic polymorphism on proton-pump inhibitor-based therapies. Drug Metab Pharmacokinet 2005;20:153-67
   PubMedGoogle Scholar
• Sakai T, Aoyama N, Kita T, et al. CYP2C10 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects. Pharm Res 2001;18:721-7
   PubMed Web of Science ®Google Scholar
• Shirai N, Furuta T, Moriyama Y, et al. Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH. Aliment Pharmacol Ther 2001;15:1929-37
   PubMed Web of Science ®Google Scholar
• Horn J. Review article: relationship between the metabolism and efficacy of proton pump inhibitors – focus on rabeprazole. Aliment Pharmacol Ther 2004;20(Suppl 6):11-19
   PubMed Web of Science ®Google Scholar
• Shimani T, Inoue M, Kuroiwa T, Horikawa Y. Rabeprazole 10 mg twice daily is superior to 20mg once daily for night-time gastric acid suppression. Aliment Pharmacol Ther 2004;19:113-22
   PubMed Web of Science ®Google Scholar
• Hu YM, Mei Q, Xu XH, et al. Pharmacodynamic and kinetic effect of rabeprazole on serum gastrin level in relation to CYP2C19 polymorphism in Chinese Hans. World J Gastroenterol 2006;12(29):4750-3
   PubMed Web of Science ®Google Scholar
• Thjodleiffson B, Cockburn I. Review article: rabeprazole's tolerability profile in the clinical trials. Aliment Pharmacol Ther 1999;13(Suppl 5):17-23
   PubMed Web of Science ®Google Scholar
• Ishizaki T, Horai Y. Review article: cytochrome P450 and the metabolism of proton pump inhibitors – emphasis on rabeprazole. Aliment Pharmacol Ther 1999;13(Suppl 3):27-36
   PubMed Web of Science ®Google Scholar
• Miner P Jr, Orr W, Filippone J, et al. Rabeprazole in nonerosive gastroesophageal relfux disease: a randomized plabcebo-controlled trial. Am J Gastroenterol 2002;97:1332-9
   PubMed Web of Science ®Google Scholar
• Kahrilas PJ, Miner R, Johanson J, et al. Efficacy of rabeprazole in the treatment of symptomatic gastroesophageal reflux disease. Dig Dis Sci 2005;50:2009-18
   PubMed Web of Science ®Google Scholar
• Fock KM, Teo EK, Ang TL, et al. Rabeprazole vs. esomeprazole in non-erosive gastro-esophageal relfux disease: a randomized, double-blind study in urban Asia. World J Gastroenterol 2005;11:3091-8
   PubMed Web of Science ®Google Scholar
• Adachi K, Hashimoto T, Hamamoto N, et al. Symptom relief in patients with reflux esophagitis: comparative study of omeprazole, lansoprazole, and rabeprazole. J Gastroenterol Hepatol 2003;18:1392-8
   PubMed Web of Science ®Google Scholar
• Thjodleifsson B, Rindi G, Fiocca R, et al. A randomized, double blind trial of efficacy and safety of 10 or 20 mg rabeprazole compared with 20mg of omeprazole in the maintenance of gastro-oesophageal reflux disease over 5 years. Aliment Pharmacol Ther 2003;13(Suppl 5):17-23
   Google Scholar
• Ponce J, Arguello L, Bastida G, et al. On-demand therapy with rabeprazole in non-erosive and erosive gastroesophageal reflux disease in clinical practice: effectiveness, health-related quality of life, and patient satisfaction. Dig Dis Sci 2004;49:931-6
   PubMed Web of Science ®Google Scholar
• Gibson PG, Henry RL, Coughlan JL. Gastro-oesophageal reflux treatment for asthma in adults and children. Cochrane Database Syst Rev 2003; Issue 1. Art. No CD001496. DOI:10.1002/14651858.CD001496
   Google Scholar
• Richter JE. Gastroesophageal reflux disease and asthma: the two are directly related. Am J Med 2000;108 4(Supp 1):153-158
   PubMed Web of Science ®Google Scholar
• Oribe Y, Fujimura M, Kita T, et al. Attenuating effect of H+K+ATPase inhibitors on airway cough by hypersensitivity induced by allergic airway inflammation in guinea-pigs. Clin Exp Allergy 2005;35: 262-7
   PubMed Web of Science ®Google Scholar
• Tsugeno H, Mizuno M, Fujiki S, et al. A proton-pump inhibitor, rabeprazole imrpoves ventilarity function in patients with asthma associated with gastroesophageal reflux. Scand J Gastroenterol 2003;38:456-61
   PubMed Web of Science ®Google Scholar
• Oribe Y, Fujimura M, Kita T, et al. Attenuating effect of H+K+ATPase inhibitors on airway cough by hypersensitivity induced by allergic airway inflammation in guinea-pigs. Clin Exp Allergy 2005;35:262-7
   PubMed Web of Science ®Google Scholar
• Klopocka M, Sinkiewicz A, Budzynski J, et al. Improvement in clinical course and laryngeal appearance in selected patient with chronic laryngitis after eight weeks of therapy with rabeprazole. Med Sci Monit 2004;10:PI 115-8
   PubMedGoogle Scholar
• Steward DL, Wilson KM, Kelly DH, et al. Proton-pump inhibitor therapy for chronic laryngo-pharyngitis: a randomized placebo controlled trail. Otolaryngol Head Neck Surg 2004;131:34250
   Google Scholar
• Qadeer MA, Phillips CO, Lopez AR, et al. Proton pump inhibitor therapy for suspected GERD-related chronic laryngitis: a meta-analysis of randomized controlled trials. Am J Gastroenterol 2006;101(11):2646-54 [Epub 13 Oct 2006]
   PubMed Web of Science ®Google Scholar
• Fuhr U, Jetter A. Rabeprazole; pharmacokinetics and pharmacokinetic drug interactions. Pharmazie 2002;57:595-601
   PubMed Web of Science ®Google Scholar
• Product information. Rabeprazole. Eisai; 2001
   Google Scholar
• Källén B. Use of omeprazole during pregnancy – no hazard demonstrated in 955 infants exposed during pregnancy. Eur J Obstet Gynecol Reprod Biol 96(1):63-8
   PubMed Web of Science ®Google Scholar
• Kallen B. Delivery outcome after the use of acid-suppressing drugs in early pregnancy with special Reference to omeprazole. Br J Obstet Gynaecol 1998;105:877-81
   PubMedGoogle Scholar
• Schardein JL, Furuhashi T, Ooshima Y. Reproductive and developmental toxicity studies of lansoprazole (ag-1749) in rats and rabbits. Yakuri Rinsho 1990;18:S2773-83. As cited by Shepard TH. Catalog of Teratogenic Agents. 8th edition, Baltimore: Johns Hopkins University Press; 1995:245
   Google Scholar
• Nielsen GL, Sorensen HT, Thulstrup AM, et al. The safety of proton pump inhibitors in pregnancy. Aliment Pharmacol Ther 1999;13:1085-9
   PubMed Web of Science ®Google Scholar
• Miner P Jr, Orr W, Filippone J, et al. Rabeprazole in nonerosive gastroesophageal relfux disease: a randomized plabcebo-controlled trial. Am J Gastroenterol 2002;97:1332-9
   PubMed Web of Science ®Google Scholar
• Vakil N, Lanza F, Schwartz H, et al. Seven-day therapy for Helicobacter pylori in the United States. Aliment Pharmacol Ther 2004;20:99-107
   PubMed Web of Science ®Google Scholar